Taurine Supplementation in Adolescents With Post-COVID Condition
- Sponsor
- University of Alberta
- Study ID
- NCT07682402
- Phase
- PHASE1/PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Long COVID
- PASC Post Acute Sequelae of COVID 19
- Post COVID-19 Condition
Eligibility Criteria
- Sex
- ALL
- Age
- 10 Years - 17 Years
- Healthy Volunteers
- Not accepted
Interventions
- Taurine — DRUGTaurine is a naturally occurring amino sulfonic acid commonly found in the body. It is marketed as a natural health product/supplement and plays an important role in the body.
Study Details
The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to experience persistent and debilitating symptoms long after the initial SARS-CoV-2 infection. This condition, known as Long COVID (LC) or sometimes referred to as Post-COVID Condition (PCC) or post-acute sequelae of COVID-19 (PASC), has emerged as a complex multisystemic condition and challenging public health issue. Contrary to initial perceptions, pediatric Long COVID is a significant health concern, with studies suggesting its prevalence ranges from 10% to 25% following infection. Research in the pediatric population has largely been limited to observational studies based on self-reported symptoms or large electronic healthcare datasets. The long-term outcomes and predictors of LC in children remain poorly described, highlighting an urgent need for further mechanistic research to characterize this complex condition. While acute COVID-19 symptoms are often milder in children relative to adults, some go on to develop a range of chronic physical, immunological, psychological, and neurological symptoms persisting for weeks to years after initial infection. The most commonly reported symptoms are similar to those seen in adults and include debilitating fatigue, respiratory distress, headaches, gastrointestinal symptoms, and neurocognitive impairment. Other frequently reported symptoms include muscle pain, sleep disturbances, olfactory and gustatory disturbances, exercise intolerance, and heart palpitations/cardiovascular symptoms. These symptoms can be new, or they may persist or fluctuate from the initial illness. Additionally, many children with LC experience psychological symptoms such as anxiety, depression, and mood disturbances, which are thought to be exacerbated by experiencing prolonged illness and subsequent lifestyle disruptions. Currently, effective treatments for LC remain elusive, leaving patients to contend with persistent symptoms that significantly impair their quality of life. For children and adolescents, these issues can profoundly impact their daily activities, academic performance, and social interactions/friendships. Symptoms like debilitating fatigue, cognitive impairment, and mood disturbances are especially disruptive by interfering with memory, energy levels, and overall development, often leading to school absenteeism, social withdrawal, and psychological distress. Therefore, it is imperative to explore novel therapeutic approaches that may alleviate the suffering of this patient population.
Key Dates
- First listed
- Jul 2, 2026
- Start date
- Sep 30, 2026
- Status verified
- Jul 2026
- Primary completion
- Mar 31, 2028
- Completion
- Dec 31, 2028
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: InterventionParticipants will receive weight-based dosing of taurine capsules administered PO twice daily.
Primary Outcome Measure
Mean Change in Plasma Taurine Levels from Baseline to Three Months [ Time Frame: Three months ]
Central Contacts
- Lawrence Richer, MD, MSc780-492-0943
- Ellen Morrison, PhD
Find similar trials
Related Studies
- Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation ResearchRecruiting · Brain Inflammation Collaborative · Delafield, Wisconsin
- CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19Recruiting · University of California, San Francisco · San Francisco, California
- The Long COVID-19 Wearable Device StudyRecruiting · Scripps Translational Science Institute · La Jolla, California
- Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2Recruiting · Stanford University · Palo Alto, California